The future of the 340B drug discount program is in jeopardy as the ongoing debate over the program intensifies. Initially, this program aimed to serve low-income patients with access to medications by requiring pharmaceutical companies to discount their drugs for providers. However, in recent years...

A recent report from the National Academies of Sciences, Engineering, and Medicine shows that the need for effective and affordable medicines is being underserved by the biopharmaceutical sector. The report is composed of eight (8) recommendations and twenty-seven (27) strategies aimed to improve prescription drug...

The 340B Drug Pricing Program "mega-guidance" spends its third month at the OMB. It is suspected that contract pharmacy arrangements will see some revisions which will reduce duplicate discounts paid by manufacturers. In the past, HRSA planned to issue a "mega-reg" that would address contract pharmacy arrangements...

Our healthcare industry is evolving into a fee-for-value payment system, which promotes value and efficiency. This new system increases the quality of care and focuses on the outcome of treatment for its patients. This industry improvement is now encountering astronomical price increases of prescription drugs...

A select group of organizations in the health and human service field have a distinct market advantage , they are able to purchase medications for consumers at a greatly reduced price through the 340B Drug Pricing Program (340B Program). As we move towards more value-based...